Source: KEI Online
Former IFPMA Chief’s (Harvey Bale’s) Quote on TPP:
Submitted by James Love on 12. June 2015
Following the Friday vote in the House of Representatives which effectively blocked movement (for now) on the Trade Promotion Authority, and more generally, slowed down the TransPacific Partnership (TPP) negotiations, I was contacted by Dr. Harvey Bale, the well known former Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). In an exchange on Facebook, Dr. Bale took favorable note of the outcome on fast track, and described the vote against fast track as “A very good day, Indeed.” I asked Dr. Bale for a statement we could use publicly for the next round of debates and he provided the following:
“I have the experience of being a former trade negotiator and senior trade official and I conclude that 1) Fast track is a poor tool for conducting trade negotiations — it encourages our negotiators NOT to negotiate hard on behalf of the general welfare (including labor); 2) secrecy of trade agreements is no longer viable, especially in an Administration that claims to give priority to transparency, since its purpose is to stack the deck against those who should be able to fairly use the democratic process to oppose something against their interest; 3) Fast track is immoral: the negative outcomes of negotiations will fall on those who are not or are ill-organized to resist. It favors the powerful over the weak.”
30 June 2015
The “Blind Agreement” report says that because lawmakers are only allowed to officially review trade laws once they have officially passed, “Parliament is faced with an all-or-nothing choice” on whether to approve the accord.
A protester holds a placard against the Trans Pacific Partnership Agreement (TPPA) during a protest outside the Global Entrepreneurship Summit on October 11, 2013 in Kuala Lumpur, Malaysia. (Photo : Getty Images)
An Australian parliamentary committee has issued a new report lambasting President Barack Obama’s Trans-Pacific Partnership (TPP) trade accord for being too secretive and lacking adequate “oversight and scrutiny.”
30 June 2015
Commerce secretary says this is the best time to conclude the deal to give a boost to textile and leather exports
New Delhi: Despite the ongoing turmoil in the euro zone over Greece’s debt crisis, India and the European Union (EU) have set a tentative August date for the resumption of stalled negotiations for a free trade agreement (FTA), with both sides keen to break the deadlock, outgoing commerce secretary Rajeev Kher said on Monday.
Source: I Am
23 June 2015
The proposed Trans-Pacific Partnership (TPP) has grabbed its fair share of headlines in both Asia and the Americas after the US House of Representatives’ dramatic rejection of a key part of the package. But although intellectual property features prominently in the deal, it may not have much of an impact on Asia’s overall IP climate even if it is passed. That’s because China and India – commonly cited as two of the most important (and problematic) markets in the region – are not party to the TPP. They are, however, both participating in negotiations for another trade agreement, the Regional Comprehensive Economic Partnership (RCEP), and recently leaked documents show that India’s policies on software and pharmaceutical patents are firmly on the agenda.
19 June 2015
The effects of patenting pharmaceutical products on access to medicines in developing countries are relatively recent as these countries have only been mandated by the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property (TRIPS) rules to grant patents on pharmaceuticals since 2005. As a result there are a limited number of empirical studies documenting these effects.
19 June 2015
China has rejected Gilead Sciences Inc’s application for a new patent related to its costly hepatitis C drug Sovaldi, removing a potential barrier to generic versions of the drug there, a U.S. legal group announced on Friday.
19 June 2015
Drug companies are going to need to take an aspirin—or three—after reading this.
A new poll finds that most Americans see drug prices as being unreasonably high—and that people are far more likely to blame drug makers than they are to point the finger at health insurance companies.